盐皮质激素受体拮抗剂在糖尿病肾病治疗中的研究进展

doi:10.16138/j.1673-6087.2023.03.015

摘要/Abstract

关键词: 盐皮质激素受体拮抗剂, 醛固酮, 肾素-血管紧张素-醛固酮系统, 糖尿病肾病, 非奈利酮

中图分类号:

R593.2

张小月, 王伟铭. 盐皮质激素受体拮抗剂在糖尿病肾病治疗中的研究进展[J]. 内科理论与实践, 2023, 18(03): 206-210.

ZHANG Xiaoyue, WANG Weiming. Research progress of mineralocorticoid receptor antagonists in treatment of diabetic nephropathy[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 206-210.

参考文献 41

[1]	Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045[J]. Diabetes Res Clin Pract, 2018, 138:271-281. doi: 10.1016/j.diabres.2018.02.023 URL
[2]	Shubrook JH, Neumiller JJ, Wright E. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations[J]. Postgrad Med, 2022, 134(4): 376-387. doi: 10.1080/00325481.2021.2009726 URL
[3]	Upadhya B, Kozak PM, Stacey RB, et al. Newer drugs to reduce high blood pressure and mitigate hypertensive target organ damage[J]. Curr Hypertens Rep, 2022, 24(1):1-20. doi: 10.1007/s11906-022-01166-9 pmid: 35165832
[4]	Baran W, Krzemińska J, Szlagor M, et al. Mineralocorticoid receptor antagonists—use in chronic kidney disease[J]. Int J Mol Sci, 2021, 22(18): 9995. doi: 10.3390/ijms22189995 URL
[5]	Zuo C, Xu G. Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy[J]. Int J Clin Pract, 2019, 29: e13413.
[6]	Hu Q, Yin L, Hartmann RW. Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases[J]. J Med Chem, 2014, 57(12): 5011-5022. doi: 10.1021/jm401430e pmid: 24422519
[7]	Dong D, Fan TT, Ji YS, et al. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes[J]. Int Urol Nephrol, 2019, 51(4): 755-764. doi: 10.1007/s11255-019-02074-9 pmid: 30734886
[8]	Choudhury D, Tuncel M, Levi M. Diabetic nephropathy—a multifaceted target of new therapies[J]. Discov Med, 2010, 10(54): 406-415.
[9]	Zhang YY, Yu Y, Yu C. Antifibrotic roles of RAAS blockers[J]. Adv Exp Med Biol, 2019, 1165: 671-691.
[10]	Sonkodi S, Mogyorósi A. Treatment of diabetic nephropathy with angiotensin Ⅱ blockers[J]. Nephrol Dial Transplant, 2003, 18 Suppl 5:v21-v23.
[11]	Hitomi H, Kiyomoto H, Nishiyama A, et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells[J]. Hypertension, 2007, 50(4): 750-755. pmid: 17646573
[12]	Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases[J]. Drug Dev Res, 2021, 82(3): 341-363. doi: 10.1002/ddr.v82.3 URL
[13]	Fujisawa G, Okada K, Muto S, et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats[J]. Kidney Int, 2004, 66(4): 1493-502. doi: 10.1111/j.1523-1755.2004.00913.x pmid: 15458443
[14]	Blankenburg M, Kovesdy CP, Fett AK, et al. Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users[J]. BMC Nephrol, 2020, 21(1): 61. doi: 10.1186/s12882-020-01719-7 pmid: 32101152
[15]	Ebadi Z, Moradi N, Kazemi Fard T, et al. Captopril and spironolactone can attenuate diabetic nephropathy in Wistar rats by targeting microRNA-192 and microRNA-29a/b/c[J]. DNA Cell Biol, 2019, 38(10): 1134-1142. doi: 10.1089/dna.2019.4732 pmid: 31433203
[16]	Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease[J]. Br J Pharmacol, 2022, 179(13):3220-3234. doi: 10.1111/bph.v179.13 URL
[17]	An J, Niu F, Sim JJ. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease[J]. Pharmacotherapy, 2021, 41(12): 998-1008. doi: 10.1002/phar.v41.12 URL
[18]	Kovarik JJ, Kaltenecker CC, Domenig O, et al. Effect of mineralocorticoid receptor antagonism and ACE inhibition on angiotensin profiles in diabetic kidney disease[J]. Diabetes Ther, 2021, 12(9): 2485-2498. doi: 10.1007/s13300-021-01118-7
[19]	Greco EA, Feraco A, Marzolla V, et al. Nonsteroidal mineralcorticoid receptor antagonists: novel therapeutic implication in the management of patients with type 2 diabetes[J]. Curr Opin Pharmacol, 2021, 60: 216-225. doi: 10.1016/j.coph.2021.07.010 pmid: 34474209
[20]	Shenoy SV, Nagaraju SP, Bhojaraja MV, et al. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: ushering in a new era of nephroprotection beyond renin-angiotensin system blockade[J]. Nephrology (Carlton), 2021, 26(11): 858-871. doi: 10.1111/nep.v26.11 URL
[21]	Chaudhuri A, Ghanim H, Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease[J]. Diabetes Obes Metab, 2022, 24(3): 365-376. doi: 10.1111/dom.v24.3 URL
[22]	Ortiz A, Ferro CJ, Balafa O, et al. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease[J]. Nephrol Dial Transplant, 2023, 38(1):10-25. doi: 10.1093/ndt/gfab167 URL
[23]	Zheng Y, Ma S, Huang Q, et al. Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease[J]. Kidney Blood Press Res, 2022, 47(4):219-228. doi: 10.1159/000521908 URL
[24]	Sawaf H, Thomas G, Taliercio JJ, et al. Therapeutic advances in diabetic nephropathy[J]. J Clin Med, 2022, 11(2): 378. doi: 10.3390/jcm11020378 URL
[25]	Filippatos G, Anker SD, Agarwal R, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes[J]. Circulation, 2021, 143(6): 540-552. doi: 10.1161/CIRCULATIONAHA.120.051898 pmid: 33198491
[26]	Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes[J]. Circulation, 2022, 145(6): 437-447. doi: 10.1161/CIRCULATIONAHA.121.057983 URL
[27]	Rossing P, Filippatos G, Agarwal R, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy[J]. Kidney Int Rep, 2022, 7(1): 36-45. doi: 10.1016/j.ekir.2021.10.008 pmid: 35005312
[28]	Janković SM, Janković SV. Clinical pharmacokinetics and pharmacodynamics of esaxerenone, a novel mineralocorticoid receptor antagonist[J]. Eur J Drug Metab Pharmacokinet, 2022, 47(3): 291-308. doi: 10.1007/s13318-022-00760-1
[29]	Wan N, Rahman A, Nishiyama A. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease[J]. J Hum Hypertens, 2021, 35(2): 148-156. doi: 10.1038/s41371-020-0377-6
[30]	Bhuiyan AS, Rafiq K, Kobara H, et al. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice[J]. Hypertens Res, 2019, 42(6): 892-902. doi: 10.1038/s41440-019-0211-0 pmid: 30664703
[31]	Ito S, Shikata K, Nangaku M, et al. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria[J]. Clin J Am Soc Nephrol, 2019, 14(8): 1161-1172. doi: 10.2215/CJN.14751218 URL
[32]	Shikata K, Ito S, Kashihara N, et al. Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease[J]. J Diabetes Investig, 2022, 13(7): 1190-1202. doi: 10.1111/jdi.v13.7 URL
[33]	Wada T, Inagaki M, Yoshinari T, et al. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study[J]. Clin Exp Nephrol, 2021, 25(2): 120-130. doi: 10.1007/s10157-020-01963-z
[34]	Ilyas Z, Chaiban JT, Krikorian A. Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy[J]. Rev Endocr Metab Disord, 2017, 18(1): 21-28. doi: 10.1007/s11154-017-9422-3 URL
[35]	Nielsen SE, Rossing K, Hess G, et al. The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP[J]. Scand J Clin Lab Invest, 2012, 72(2): 137-142. doi: 10.3109/00365513.2011.645055 URL
[36]	Baran W, Krzemińska J, Szlagor M, et al. Mineralocorticoid receptor antagonists-use in chronic kidney disease[J]. Int J Mol Sci, 2021, 22(18): 9995. doi: 10.3390/ijms22189995 URL
[37]	Zhang Q, Yang M, Xiao Y, et al. Towards better drug repositioning: targeted immunoinflammatory therapy for diabetic nephropathy[J]. Curr Med Chem, 2021, 28(5): 1003-1024. doi: 10.2174/0929867326666191108160643 URL
[38]	Lytvyn Y, Bjornstad P, Pun N, et al. New and old agents in the management of diabetic nephropathy[J]. Curr Opin Nephrol Hypertens, 2016, 25(3): 232-239. doi: 10.1097/MNH.0000000000000214 URL
[39]	Rossing P, Persson F, Frimodt-Møller M, et al. Linking kidney and cardiovascular complications in diabetes-impact on prognostication and treatment[J]. Diabetes, 2021, 70(1):39-50. doi: 10.2337/dbi19-0038 pmid: 33355308
[40]	Cortinovis M, Cattaneo D, Perico N, et al. Investigational drugs for diabetic nephropathy[J]. Expert Opin Investig Drugs, 2008, 17(10): 1487-500. doi: 10.1517/13543784.17.10.1487 URL
[41]	Roscioni SS, Heerspink HJ, de Zeeuw D. The effect of RAAS blockade on the progression of diabetic nephropathy[J]. Nat Rev Nephrol, 2014, 10(2): 77-87. doi: 10.1038/nrneph.2013.251 pmid: 24296623

盐皮质激素受体拮抗剂在糖尿病肾病治疗中的研究进展

Research progress of mineralocorticoid receptor antagonists in treatment of diabetic nephropathy

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

编辑推荐

Metrics

本文评价

[1]	毕礼明, 王朝晖. 糖尿病肾病发病机制研究进展[J]. 内科理论与实践, 2023, 18(03): 201-205.
[2]	赖莉琴, 龚艳春. 原发性醛固酮增多症慢性肾损伤的研究进展[J]. 内科理论与实践, 2023, 18(03): 211-214.
[3]	中华医学会内分泌学分会. 肾上腺疾病新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 16-17.
[4]	中华医学会内分泌学分会. 新型冠状病毒肺炎疫情下肾上腺疾病管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 139-142.
[5]	孙艳, 代丹娇, 陈智伟, 张华清. 卡格列净对早期糖尿病肾病尿白蛋白/肌酐比值和尿足细胞相关蛋白裂隙素的影响[J]. 内科理论与实践, 2021, 16(06): 387-391.
[6]	缪雅, 杨玉琳, 朱怡洁, 盛长生, 田景琰. 糖化血红蛋白变异性与糖尿病微血管并发症关系的研究进展[J]. 内科理论与实践, 2021, 16(06): 427-430.
[7]	胡哲, 陈歆, 罗芳秀, 初少莉, 王继光. 肾上腺醛固酮和皮质醇共分泌瘤一例报告[J]. 诊断学理论与实践, 2020, 19(05): 525-527.
[8]	王春花, 祁爽, 王敏. 原发性醛固酮增多症合并无痛性心肌梗死一例报告[J]. 诊断学理论与实践, 2020, 19(05): 528-530.
[9]	蒋怡然, 王卫庆. 原发性醛固酮增多症的诊治现状及展望[J]. 诊断学理论与实践, 2020, 19(05): 445-449.
[10]	陈歆, 程艾邦, 许建忠, 李燕, 王继光. 中国高血压患者原发性醛固酮增多症的前瞻性筛查研究进展[J]. 诊断学理论与实践, 2020, 19(05): 450-453.
[11]	中国高血压联盟. 高血压患者原发性醛固酮增多症筛查诊治流程[J]. 诊断学理论与实践, 2020, 19(05): 454-459.
[12]	程艾邦, 李明轩, 陈波, 曹晟, 蒋塨豪, 许建忠, 李燕, 王继光. 化学发光免疫分析法检测血浆肾素、醛固酮在原发性醛固酮增多症诊断中的价值[J]. 诊断学理论与实践, 2020, 19(05): 474-480.
[13]	李淑雨, 沈琳辉,. 2型糖尿病患者参考范围甲状腺激素与糖尿病肾病的相关性分析[J]. 内科理论与实践, 2020, 15(01): 38-44.
[14]	邓琳, 丁怡, 汪萍, 卞炳贤, 沈立松. 尿中性粒细胞明胶酶相关脂质运载蛋白/肌酐比值在2型糖尿病肾损伤的早期诊断及病情评估中的临床应用[J]. 诊断学理论与实践, 2019, 18(1): 61-65.
[15]	康健捷, 苏佩珣, 邓兵梅, 杨红军, 王卓才. 肾上腺腺瘤型原发性醛固酮增多症并发横纹肌溶解症一例[J]. 诊断学理论与实践, 2019, 18(05): 583-584.